Diabetes cell therapies take evasive action
Elie Dolgin • February 25, 2022
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Continue reading at Nature Biotechnology.
With a call of 130 decibels, the bare-throated bellbird is a big-beaked marvel.
Autonomous blood-drawing devices could help address phlebotomist shortages.